Versi Ebrahim 4
4 · DMK PHARMACEUTICALS Corp · Filed Sep 19, 2023
Insider Transaction Report
Form 4
Versi Ebrahim
DirectorCEO
Transactions
- Conversion
Common Stock
2023-09-15+729,200→ 906,394 total(indirect: By LLC) - Conversion
Series E Convertible Preferred Stock
2023-09-15−729.2→ 1,212 total(indirect: By LLC)From: 2023-05-25→ Common Stock (729,200 underlying)
Holdings
- 8,745
Common Stock
Footnotes (2)
- [F1]On September 15, 2023, Versi Group, LLC converted 729.2 shares of Series E Convertible Preferred Stock ("Series E Preferred") into 729,200 shares of Common Stock, pursuant to the terms of the Series E Preferred. Each share of Series E Preferred is convertible into 1,000 shares of Common Stock at the election of the reporting person, subject to certain beneficial ownership limitations. The Series E Preferred has no expiration date.
- [F2]The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the manager and a member. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interests therein.